Streetbeat News

Price Targets

STVN

Morgan Stanley analyst Drew Ranieri reiterated an Overweight rating on Stevanato Gr (NYSE:STVN) and maintained a $29 price target.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2023 | 1:37 pm

KA

Zacks Small-Cap Research has set a price valuation of $13.50 for Kineta, a biotechnology company focused on developing novel immunotherapies. The valuation is based on the company's pipeline and potential market opportunities.

Portfolio Pulse from Happy Mohamed

June 20, 2023 | 1:36 pm

TYGO

Craig-Hallum analyst Eric Stine initiates coverage on Tigo Energy (NASDAQ:TYGO) with a Buy rating and announces a price target of $28.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 1:35 pm

AGL

Truist Securities analyst Jailendra Singh maintains a Buy rating on Agilon Health (NYSE:AGL) but lowers the price target from $35 to $27.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 1:30 pm

CI

Truist Securities analyst David Macdonald maintains a Buy rating on Cigna Group (NYSE:CI) but lowers the price target from $375 to $365.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 1:29 pm

THC

Truist Securities analyst Ryan MacDonald maintains a Buy rating on Tenet Healthcare (NYSE:THC) and raises the price target from $84 to $92.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 1:28 pm

NOG

Truist Securities analyst Neal Dingmann maintains a Buy rating on Northern Oil & Gas (NYSE:NOG) and raises the price target from $58 to $60.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 1:27 pm

SPOT

Morgan Stanley analyst Manan Gosalia reiterated an Overweight rating on Spotify Technology (NYSE:SPOT) and maintained a $170 price target.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2023 | 1:27 pm

MOH

Truist Securities analyst David Macdonald maintains a Buy rating on Molina Healthcare (NYSE:MOH) but lowers the price target from $380 to $365.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 1:26 pm

HUM

Truist Securities analyst David Macdonald maintains a Hold rating on Humana (NYSE:HUM) and lowers the price target from $590 to $530.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 1:26 pm